DAP-CORONA
The DAP-CORONA RCT is a phase III randomized, triple-blind, placebo-controlled multi-center study on the efficacy and safety of Dapsone in adult patients who have been presenting with symptoms, have been diagnosed with COVID-19 infection and are at high risk of developing complications and requiring hospitalization. Approximately 3 000 individuals who meet the eligibility criteria of this trial will be selected to receive either Dapsone, a generic drug, or placebo tablets for 21 days on a random basis.